Kornimate/medical-research-clean huggingface dataset:
18f-dcfpyl positron emission tomography (pet)/computed tomography (ct) in men with prostate cancer

Conditions: Prostatic Neoplasms

Summary: pyl, also known as \[18f\]dcfpyl, is a second-generation fluorinated prostate-specific membrane antigen (psma) targeted pet imaging agent. in preliminary studies it demonstrates a higher detection of metastatic prostate lesions compared to standard imaging. its ability to image metastatic prostate cancer sites was comparable to 68ga-psma with high tumor-to-background ratios.additionally, \[18f\] pyl demonstrated higher mean tumor-to-background ratios when using kidney, spleen, or parotid as reference organs. however, the role of \[18f\] pyl in tumor response to therapy has not been evaluated, specifically the potential to serve as a predictive biomarker of response. given the high cost of current therapeutic agents in mcrpc, there is a need for an early response biomarker to stratify which patients will benefit from therapy and which will not. this will also allow for earlier change in management of patients who will not response to these therapies, potentially improving patient outcomes.

the investigators will conduct a prospective phase ii/iii study of 300 men diagnosed with prostate cancer with a rising prostate-specific antigen (psa). upon enrollment, subjects will undergo standard of care imaging (defined as a ct or mri of the chest, abdomen, and pelvis, and 99mtc bone scans) if not obtained within 45 days of enrollment. subjects will have standard of care laboratory evaluations and undergo 18f- dcfpyl pet/ct. \[18f\]dcfpyl will be used for study imaging.

Eligibility criteria:
inclusion criteria: 1. histologically confirmed diagnosis of prostate cancer 2. psa ≥ 0.2ng/ml 3. age ≥ 18 years of age 4. eastern cooperative oncology group (ecog) performance status ≤ 2 (karnofsky ≥ 60%) 5. ability to understand and willingness to sign a written informed consent document 6. wiling to comply with clinical trial instructions and requirements 7. willing to cover the cost of pyl pet/ct imaging if funds are not available exclusion criteria: 1. history of another active malignancy within 3 years, other than basal cell and squamous cell carcinoma of the skin 2. presence of prostate brachytherapy implants unless approved by the pi 3. administration of another radioisotope within five physical half-lives of trial enrollment 4. radiation or chemotherapy within 2 weeks prior to trial enrollment 5. serum creatinine \> 3 times the upper limit of normal 6. serum total bilirubin \> 3 times the upper limit of normal 7. aspartate transaminase (ast) or alanine aminotransferase (alt) \>5 times the upper limit of normal 8. inadequate venous access
evaluation of multiple subgingival irrigations.

Conditions: Periodontitis, Adult

Summary: the study will be conducted at the department of periodontology, cliniques universitaires saint luc. patients diagnosed with generalized chronic periodontitis (gchp) based on the current classification of the american academy of periodontology will be included. detailed medical, periodontal and dental history will be obtained. those who will fulfill the inclusion/exclusion criteria will be invited to participate in the study.

the study will be conducted at the department of periodontology, cliniques universitaires saint luc. the patients will be informed in detail of the nature and course of study, and will sign informed consent prior to engagement in the study. patients diagnosed with gchp based on the current classification of the american academy of periodontology will be included. detailed medical, periodontal and dental history will be obtained. those who will fulfill the inclusion/exclusion criteria will be invited to participate in the study.

Eligibility criteria:
inclusion criteria: * ≥ 30 years of age * at least 15 teeth (excluding third molars and teeth with advanced decay indicated for extraction) * any history of periodontal treatment in the previous 6 months * no removable prosthesis * a minimum of 6 teeth with at least one site each with periodontal probing depth (ppd) and clinical attachment level (cal) ≥5 mm * at least 30% of the sites with ppd and cal ≥4 mm and bleeding on probing (bop) exclusion criteria: * any sensitivity or allergy to any of the products that will be used in the study * thyroid dysfunction * systemic disease (asa ii or more) * need for antibiotic pre-medication for routine dental therapy * antibiotic therapy in the previous 3 months * pregnancy and breastfeeding * current smokers (more than 5 cigarettes a day)
improving smoking cessation outcomes in heavy drinkers - 1

Conditions: Tobacco Use Disorder

Summary: to test the effectiveness of an smoking cessation treatment for smokers who also drink alcohol heavily.

heavy alcohol use frequently co-occurs with cigarette smoking and may impede smoking cessation. this clinical trial examined whether smoking cessation treatment that incorporates brief alcohol intervention can improve smoking cessation outcomes (7-day verified point prevalence abstinence) and reduce drinks consumed per week. heavy drinkers seeking smoking cessation treatment were assigned by urn randomization to receive, along with 8-weeks of nicotine replacement therapy, either a 4-session standard smoking cessation treatment (st, n = 119) or standard treatment of equal intensity that incorporated brief alcohol intervention (st-bi, n = 117).

Eligibility criteria:
inclusion criteria: 1. be at least 18 years of age 2. have smoked cigarettes regularly for at least one year 3. currently smoke at least 10 cigarettes a day 4. currently be using no other tobacco products or nicotine replacement therapy 5. currently drink heavily according to self-report (\>14 drinks per week or \>5 drinks per occasion at least once per month over the last 12 months for men; \>7 drinks per week or \>4 drinks per occasion at least once per month over the past 12 months for women) exclusion criteria: 1. meet full dsm-iv criteria for alcohol dependence in the past 12 months 2. meet criteria for other current psychoactive substance abuse or dependence (excluding nicotine dependence and alcohol abuse) in the past 12 months \[this would also exclude individuals with lifetime substance dependence who continue to have some abuse/dependence symptoms in the past 12 months\] 3. meet criteria for current dysthymia, major depression, or manic episode \[past month\] 4. are currently psychotic \[past 12 months\] or suicidal \[suicidal ideation or intent in the past month\] 5. have an unstable medical condition that would suggest caution in the use of the nicotine patch (e.g., unstable angina pectoris, arrhythmia, recent congestive heart failure) 6. are currently pregnant or lactating or intend to become pregnant. we also will exclude participants who are not alcohol dependent but who have characteristics that might make supervised alcohol detoxification necessary (e.g., morning drinking to avoid withdrawal, daily drinking of \>12 drinks, recent withdrawal symptoms, history of severe withdrawal symptoms such as hallucinations, seizures, or delirium tremens).

Keywords: tobacco alcohol
impact of perioperative body composition abnormalities on patient outcomes after liver transplantation

Conditions: Liver Transplantation; Body Composition

Summary: accumulating evidence suggests the prognostic significance of body composition in chronic diseases and neoplastic diseases. ct imaging-based body composition abnormalities are significantly associated with post-lt adverse outcomes including decreased quality of life (qol), impaired graft regeneration and mortality. however, the perioperative changes in body composition and their potential clinical implications remain unexplored. the objective of this study is to systematically explore and clarify the correlation between body composition and the prognosis of liver transplant patients through dynamic peri-transplant mornitoring.


Eligibility criteria:
inclusion criteria: * adult patients undergoing deceased donor liver transplantation (ddlt) for the first time. exclusion criteria: * pediatric transplants * re-transplants * multi-organ transplants * liver cancer patients with macrovascular invasion or distant metastasis * patients who died within 30 days after transplantation
attachment and post-traumatic stress disorder in military personnel: characterization of the french military population, exploration of biopsychosocial factors, and study of the impact of security priming on emotional contagion capacities

Conditions: Post-traumatic Stress Disorder (PTSD); Emotional Contagion

Summary: post-traumatic stress disorder (ptsd) is a pathology that impairs the quality of life of sufferers. in military personnel, it can lead to military incapacity. this psychopathology is characterized by confrontation with one or more traumatic events in the individual's life history. symptoms include cognitive and mood disorders, avoidance, hyperactivation (hypervigilance and anger) and intrusions (flashbacks and nightmares). studies show that the prevalence of ptsd in military personnel fluctuates considerably from one situation to another (pre-deployment/post-deployment, etc.). in these at-risk populations, the often more complex ptsd clinic may also account for the heterogeneity of prevalences observed. nevertheless, ptsd tends to become chronic in military personnel, making it particularly difficult to return to a "previous" state. in french casualties, beyond the symptoms already mentioned, complaints focus on difficulties in social interaction situations involving others in social life (attachment style to others) and in everyday life (public transport, supermarket shopping, social interactions, presence of crowds...). in the context of post-traumatic stress disorder, we would like to explore the processes of social cognition that enable people to interact in their environment, in relation to biological, psychosocial and physiological variables that may constitute risk or maintenance factors for the pathology.


Eligibility criteria:
inclusion criteria: inclusion criteria common to both groups: * volunteers who agreed to participate in the study and provided written consent * affiliated with social security * proficient in the french language inclusion criteria specific to the "military personnel with ptsd" group: * military personnel diagnosed with post-traumatic stress disorder related to their duties * participants in activities offered by the wounded service support units exclusion criteria: * adults subject to a protective measure * refusal to participate in the study * unrectified legionnaires

Keywords: ptsd complex ptsd military veteran emotional contagion oxytocin vasopressine
a retrospective nis to evaluate the use of seroquel xr and ir in the clinical practice of outpatients with schizophrenia

Conditions: Schizophrenia

Summary: the primary objective of this non-interventional study is to investigate how seroquel xr and seroquel ir are used in the clinical practice of outpatients with schizophrenia. this will be done by a retrospective review of medical records to evaluate patients treated with seroquel xr or seroquel ir as primary antipsychotic treatment.


Eligibility criteria:
inclusion criteria: * adults with a diagnosis of schizophrenia from a district psychiatric clinic in denmark * patients who have received at least one dose of seroquel xr or seroquel ir during january - march 2010 exclusion criteria: * patients already participating in a clinical study during the study-period.

Keywords: mental disorder antipsychotic treatment
interferon α 2b pharmacovigilance study

Conditions: Hepatitis C, Chronic

Summary: multicenter prospective follow-up of a not controlled chronic hepatitis c genotypes 2/3 patients cohort with treatment indication with interferon α 2b and ribavirin for 24 weeks, and the verification of sustained virological response at week 48. the eligibility criteria and outcome measures followed the clinical protocol and therapeutic guidelines for chronic viral hepatitis c, published by the ministry of health: http://portal.saude.gov.br/portal/arquivos/pdf/pcdt_hepatite_c_2011_retificado.pdf


Eligibility criteria:
inclusion criteria: * genotype 2/3 chronic hepatitis c confirmed by biomolecular technology (rnavhc); * treatment naive; * signing the informed consent form; * eligibility criteria and outcome measures followed the clinical protocol and therapeutic guidelines for chronic viral hepatitis c, published by the ministry of health: http://portal.saude.gov.br/portal/arquivos/pdf/pcdt_hepatite_c_2011_retificado.pdf exclusion criteria: * serious adverse events; * intolerance to treatment; * lost to follow up.

Keywords: hepatitis c, chronic genotype 2/3 interferon α 2b ribavirin pharmacovigilance
interest of pregabalin (lyrica) on the treatment of reflex earache in head and neck cancer.

Conditions: Earache

Summary: referred otalgia is one of the symptoms of oropharynx and hypopharynx cancer. it can be primary (otodynia) or secondary (referred otalgia and projected pain). the mechanism of referred otalgia involves several non adjacent nerve territories as those of head, neck or ear. referred otalgia is a projected pain due to injury (most of the time cancer) localized far from the ear but sharing the same innervation. in this contest, the otoscopy is normal. four cranial nerves participate in the sensory innervation of the external ear: the trigeminal nerve (v) via the auriculo temporal nerve (v3), the facial nerve (vii) for the ramsay-hunt's zone with the conch, tragus, antitragus, a part of the anthelix, of the external auditory meatus and of the eardrum, the glossopharyngeal nerve (ix) via the jacobson's nerve for the external ear canal and the c2 and c3 cervical plexus. however, there are important interindividual anatomical variations. the relationship between referred otalgia and probable nerve damage has been described. in he oropharynx and hypopharynx, the proximity of the sensory innervation of the ear can then explain the otalgia during the cancer progression. then referred otalgia has a neuropathic component. in the literature, the curative treatment of referred otalgia is the cancer treatment. however, the high intensity of referred otalgia leads the patients to a large consumption of analgesics in particular of opioids. these latter are particularly adapted for pain resulting from excess of nociceptive stimulation. pregabalin (lyrica®) is an analogue of gamma aminobutyric acid. this molecule binds to alpha subunit 2 delta 1 calcium dependent voltage channels in the central nervous system. its effectiveness has been demonstrated for the treatment of neuropathic pain on diabetic neuropathy, post herpetic neuralgia, lesions in the bone marrow but also the postoperative pain when the molecule is administered after the surgery. the anti hyperalgesic activity of pregabalin is at a dosage of 150mg/day in two or three daily doses. the purpose of this study was to evaluate the activity of pregabalin administered orally for three weeks after the anesthesia consultation on the intensity of the pain of referred otalgia and on its neuropathic component.


Eligibility criteria:
inclusion criteria: * referred otalgia * ent cancer * asa score 1,2 or 3 * understanding protocol * information and free and informed consent exclusion criteria: * asa score 4 et 5 * allergy or intolerance of pregabalin * creatinin clearance inferior of 50ml/min (cockcroft formula) * liver failure * cardiac failure * history epilepsy * ant hyperalgesic treatment * minor or disabled adult * intellectual disabilities that prevent the understanding of the protocol * uncooperative patient * pregnant women * patient participating in another research protocol * lactose intolerant patient

Keywords: neuropathic pain, ent cancer, pregabalin
deprescribing drrugs for overactive bladder in general practice (drop)

Conditions: Overactive Bladder; Deprescribing; PIMS

Summary: the objective is to understand and evaluate the effectiveness of a deprescribing intervention in primary care, specifically targeting medications for overactive bladder in individuals aged 65 or older.

potentially inappropriate medication is prescribed medications with an unfavorable risk-benefit profile, for which there might be better, safer, or more cost-effective alternatives. anticholinergic drugs for overactive bladder (oab) is an example of a potentially inappropriate medication in the elderly, calling for attention and possible deprescribing. due to their crucial role in maintaining a patient's medication regimen, primary care settings are widely regarded as the optimal location for conducting medication reviews and deprescribing interventions. this study utilizes a mixed methods explanatory sequential design, nested in a randomised controlled trial to explore deprescribing drugs for overactive bladder (oab). general practices will be randomized into two groups. the intervention group will then be evaluated in a mixed methods setup and finish the study with a comparison to the control group. the mixed methods approach employs a quantitative approach following the intervention group and investigates the prevalence of deprescribing the drugs in question. secondly, a qualitative approach will be used to delve into the experiences of general practitioners (gps), support staff, and patients during the deprescribing process. finally, the quantitative and qualitative findings are merged to gain a comprehensive understanding of deprescribing for oab. this integrated approach enhances insights and informs future interventions and recommendations. after the mixed methods studies are completed the control group will be used in an overall comparison of the two groups using registry data

Eligibility criteria:
inclusion criteria: * patient must have been prescribed one of the following drugs for oab within the last 14 months * patient must be able to speak and understand danish exclusion criteria: * too cognitively impaired to participate or otherwise unfit to participate as estimated by general practitioner * receiving neurological or urogenital ambulatory care for their overactive bladder symptoms
mediterranean diet for post-menopausal women: effects on bone turnover

Conditions: Osteoporosis; Postmenopausal Bone Loss

Summary: the investigators propose a 24 week clinical research trial (12 week observational period followed by 12 week medsd intervention) with feasibility of diet adoption and markers of bone turnover as the primary outcomes.

postmenopausal women are at increased risk of osteoporosis and fracture. components of a mediterranean style diet (medsd) are associated with reduced bone loss and fracture risk; however, the medsd has not been tested in this population in the u.s. therefore, fhe investigators propose a 24 week clinical research trial (12 week observational period followed by 12 week medsd intervention) with feasibility of diet adoption and markers of bone turnover as the primary outcomes. the 12 week intervention will include provision of olive oil, walnuts and high n-3 polyunsaturated fatty acids (pufa) fish to replace other fats and oils, processed snacks and red meat, respectively; accompanied with fruit, vegetable, whole grain and legumes intake recommendations. the investigators hypothesize the medsd intervention will increase serum n-3 pufa and decrease saturated fatty acids and n-6 pufa and this will result in an improvement in bone turnover markers. the outcomes of the proposed intervention trial will promote further study of the benefits of a medsd in the us. the investigators envision the research team to expand to other systems such as cardiovascular, metabolic, and inflammatory mechanisms in which less risk of disease is associated with a medsd.

Eligibility criteria:
inclusion criteria: * postmenopausal women \> 65 years * bmi\<30 kg/m2 * able to travel to clinical sites for follow-up visits * willing to make no changes to habitual physical activity or calcium and vitamin d intake for the study duration exclusion criteria: * any disease that may affect bone metabolism, (i.e paget's disease, primary hyperparathyroidism) * cancers of any kind (except basal or squamous cell of skin) in past 5 years * use of medication known to affect bone metabolism * extreme dietary behaviors or supplementation in excess of dri upper limits * following a medically prescribed diet or dietary pattern similar to the medsd * history of chronic renal or liver disease * history of hip fracture or known vertebral fracture within the past year * persons with an allergy to fish or nuts.

Keywords: mediterranean diet bone turnover postmenopausal women
specimen banking from patients with lung cancer

Conditions: Lung Neoplasms

Summary: the primary objective of the protocol is to develop a comprehensive specimen banking program from patients with lung cancer for future translation research, which will enable the investigators to detect lung cancer earlier, develop better therapies and explore screening and prevention strategies.

the aims of the study are as follows: 1) to continue to unravel the complex biology of lung cancer 2) to identify early detection and prognostic markers to guide therapeutic decision 3) to define markers of response and/or resistance to drug therapy, and 4) to identify new therapeutic and prevention targets.

Eligibility criteria:
inclusion criteria: 1. subjects who are undergoing further testing for the diagnosis or treatment of lung cancer. 2. oral and written informed consent exclusion criteria: 1. any individual who does not give oral and written consent for participation

Keywords: lung cancer
mpfl vs campbell in recurrent patella dislocation

Conditions: Recurrent Patella Dislocation

Summary: this study will compare anatomic medial patellofemoral reconstruction from hamstring graft with non anatomic reconstruction according to campbell. the purpose of this study is to evaluate which type of treatment recurrent patella dislocation provides to better clinical, radiological and laboratory outcomes.

recurrent patella dislocation require surgery treatment. it provides to less cartilage degeneration and slow down knee osteoarthritis. medial retinacular complex is injured in first time patella dislocation and its reconstruction is necessary. in literature there can be found many surgical reconstruction technics: anatomical or non anatomical (functional). but there is lack of evidence which technic provides to better outcomes - reduce the possibility to patella dislocation and progression of osteoarthritis in patellofemoral joint. nowadays the choice of performed surgery depends on surgeons personal assessment.

Eligibility criteria:
inclusion criteria: * recurrent patella dislocation * no patellofemoral joint dysplasia or dysplasia a/b according to dejour (non operating) * acceptable is to perform concomitant medialization tibial tubercle osteotomy exclusion criteria: * no informed consent to participate in the study * age under 18 years or above 65 * multiligament injury or single plane knee instability * another musculoskeletal disorders in lower limb * lower limb deformity requiring axis correction: valgus * femoral anteversion (ct measurements) * joints inflammatory diseases * concomitant patellectomy or trochleoplasty * asa score \> ii

Keywords: mpfl campbell